Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

How the QA and QP talent market is changing in pharma

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Regulatory

Andelyn Biosciences strengthens CDMO credentials with full ICMC certification

The certification received by Andelyn underscores their long-standing commitment to quality, operational readiness, and client service as the company supports innovators in advancing gene therapies from development through clinical and commercial manufacturing
Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Regulatory

FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome

AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
Subscribe now